title: Resveratrol plus carboxymethyl-β-glucan in children with recurrent respiratory infections: a preliminary and real-life experience.
abstract: BACKGROUND
  Recurrent respiratory infections (RRI), such as the presence of at least one of the following criteria: i) >6 RI per year; ii) >1 RI per month involving upper airways from September to April; iii) >3 RI involving lower airways, constitute a social problem for both their pharmaco-economic impact and the burden for the family. However, several treatment have been proposed with controversial results.
  
  
  OBJECTIVE
  As resveratrol plus carboxymethyl-β-glucan is presently available as solution for aerosol, the aim of this study was to evaluate the effects of this compound, compared to saline solution, whether it is able to prevent RRI in children.
  
  
  METHODS
  The study was designed as real-life, randomized. Globally, 82 children (49 males, mean age 8.1 ± 2.6 years) with acute rhinopharyngitis and RRI were enrolled. Resveratrol plus carboxymethyl-β-glucan or saline isotonic solution was randomly (ratio 1:1) administered immediately after an anti-infective and anti-inflammatory 10-day treatment (tiamphenicol associated with acetylcysteine plus beclomethasone dipropionate) for the acute rhinopharyngitis. Investigated treatments lasted 20 days. Days with respiratory symptoms, fever, medication use, medical visits, and school absences were evaluated. Children were visited 30, 60, and 90 days after starting treatments.
  
  
  RESULTS
  The active compound was able to significantly reduce the number of days with nasal obstruction (p < 0.001), rhinorrhea (p < 0.001), sneezing (p < 0.001), cough (p = 0.002), fever (p < 0.001), medication use (p < 0.001), medical visits (p < 0.001), and school absence (p < 0.001).
  
  
  CONCLUSIONS
  This preliminary and real-life study could suggest that an aerosolized solution containing resveratrol plus carboxymethyl-β-glucan might exert preventive effects in children with RRI.
authors.affiliation: Associazione Italiana Vie Aeree (AIVAS): Study Group on Respiratory Infections, Via P. Boselli 5, 16146, Genoa, Italy. alfonso.varricchio@gmail.com.
authors.forename: Alfonso Maria
authors.initials: AM
authors.lastname: Varricchio
authors.affiliation: Associazione Italiana Vie Aeree (AIVAS): Study Group on Respiratory Infections, Via P. Boselli 5, 16146, Genoa, Italy. mic.capasso@gmail.com.
authors.forename: Michele
authors.initials: M
authors.lastname: Capasso
authors.affiliation: Associazione Italiana Vie Aeree (AIVAS): Study Group on Respiratory Infections, Via P. Boselli 5, 16146, Genoa, Italy. antonio.dellavolpe@gmail.com.
authors.forename: Antonio
authors.initials: A
authors.lastname: Della Volpe
authors.affiliation: Associazione Italiana Vie Aeree (AIVAS): Study Group on Respiratory Infections, Via P. Boselli 5, 16146, Genoa, Italy. luigi.malafronte@gmail.com.
authors.forename: Luigi
authors.initials: L
authors.lastname: Malafronte
authors.affiliation: Associazione Italiana Vie Aeree (AIVAS): Study Group on Respiratory Infections, Via P. Boselli 5, 16146, Genoa, Italy. nicola.mansi@libero.it.
authors.forename: Nicola
authors.initials: N
authors.lastname: Mansi
authors.affiliation: Associazione Italiana Vie Aeree (AIVAS): Study Group on Respiratory Infections, Via P. Boselli 5, 16146, Genoa, Italy. attilio.varricchio@aivas.it.
authors.forename: Attilio
authors.initials: A
authors.lastname: Varricchio
authors.affiliation: Associazione Italiana Vie Aeree (AIVAS): Study Group on Respiratory Infections, Via P. Boselli 5, 16146, Genoa, Italy. gio.cip@libero.it.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Ciprandi
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008016:Life Change Events; D008297:Male; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents; D047071:beta-Glucans / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013267:Stilbenes; D014665:Vasodilator Agents; D047071:beta-Glucans; C066878:carboxymethyl-beta-glucan-cytarabine; D003561:Cytarabine; D000077185:Resveratrol